WI
RPRX icon

WBI Investments’s Royalty Pharma RPRX Stock Holding History

WBI Investments’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,857
Closed -$281K – 351
2026
Q1 		$281K Buy
+5,857
New +$257K 0.08% 246
2025
Q4 		– Sell
-54,266
Closed -$1.91M – 377
2025
Q3 		$1.91M Buy
+54,266
New +$1.96M 0.49% 49

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

WBI Investments's RPRX Position: Q2 2026 in Review

WBI Investments sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 5,857 shares — an estimated $281K sold.

WBI Investments first reported a position in RPRX in Q3 2025 and held it in 2 quarters. The position peaked at $1.91M in Q3 2025. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • WBI Investments reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • WBI Investments sold 5,857 Royalty Pharma shares in Q2 2026, an estimated $281K.
  • WBI Investments first reported a position in Royalty Pharma in Q3 2025 and held it in 2 quarters.
  • WBI Investments's Royalty Pharma position peaked at $1.91M in Q3 2025.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on WBI Investments's 13F filing for Q2 2026, filed 11 Aug 2026.